Kousted Tina M, Kalliokoski Otto, Christensen Sofie K, Winther Jakob R, Hau Jann
Department of Experimental Medicine, University of Copenhagen, Denmark; Linderstrøm-Lang Centre for Protein Science, Department of Biology, University of Copenhagen, Denmark.
Department of Experimental Medicine, University of Copenhagen, Denmark.
Heliyon. 2017 Mar 16;3(3):e00267. doi: 10.1016/j.heliyon.2017.e00267. eCollection 2017 Mar.
Hens have a tremendous capacity for producing polyclonal antibodies that can subsequently be isolated in high concentrations from their eggs. An approach for further maximizing their potential is to produce multiple antisera in the same individual through multiplexed (multiple simultaneous) immunizations. An unknown with this approach is how many immunogens a single bird is capable of mounting a sizeable antigenic response toward. At what point does it become counter-productive to add more immunogens to the same immunization regimen? In the present study we were able to demonstrate that the competing effects of co-administering multiple immunogens effectively limit the antibody specificities that can be raised in a single individual to a fairly low number. Two potent model immunogens, KLH and CRM, were administered together with competing antigens in various concentrations and complexities. With an upper limit of 1 mg protein material recommended for chicken immunizations, we found that the maximum number of immunogens that can be reliably used is most likely in the low double digits. The limiting factor for a response to an immunogen could not be related to the number of splenic plasma cells producing antibodies against it. When administering KLH alone, up to 70% of the IgY-producing splenic plasma cells were occupied with producing anti-KLH antibodies; but when simultaneously being exposed to a plethora of other antigens, a response of a comparable magnitude could be mounted with a splenic plasma cell involvement of less than 5%. Two breeds of egg-layers were compared with respect to antibody production in an initial experiment, but differences in antibody productivity were negligible. Although our findings support the use of multiplexed immunizations in the hen, we find that the number of immunogens cannot be stretched much higher than the handful that has been used in mammalian models to date.
母鸡具有产生多克隆抗体的巨大能力,随后可以从它们的鸡蛋中以高浓度分离出这些抗体。进一步最大化其潜力的一种方法是通过多重(同时进行多次)免疫在同一个体中产生多种抗血清。这种方法的一个未知之处在于,一只鸡能够对多少种免疫原产生可观的抗原反应。在同一免疫方案中添加更多免疫原到什么程度会适得其反?在本研究中,我们能够证明同时给予多种免疫原的竞争效应有效地将单个个体中能够产生的抗体特异性限制在相当低的数量。两种有效的模型免疫原,钥孔血蓝蛋白(KLH)和交叉反应性突变体(CRM),与不同浓度和复杂性的竞争抗原一起给药。由于建议用于鸡免疫的蛋白质材料上限为1毫克,我们发现能够可靠使用的免疫原的最大数量很可能在个位数的低值。对免疫原反应的限制因素与产生针对它的抗体的脾浆细胞数量无关。单独给予KLH时,高达70%产生IgY的脾浆细胞忙于产生抗KLH抗体;但当同时暴露于大量其他抗原时,脾脏浆细胞参与度低于5%时也能产生相当程度的反应。在最初的实验中比较了两个产蛋鸡品种的抗体产生情况,但抗体产生效率的差异可以忽略不计。虽然我们的研究结果支持在母鸡中使用多重免疫,但我们发现免疫原的数量不能比迄今为止在哺乳动物模型中使用的少数几种增加太多。